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In the Spring 1994 issue of Health Affairs, Stephen
H. Long, Ph.D., senior economist at RAND and the
executive director of the short-lived Prescription Drug
Payment Review Commission, raised the following
questions in his article “Prescription Drugs and the
Elderly: Issues and Options.”
 Whose responsibility is it to provide coverage?
 Who should be covered?
 What should be covered?
 Who should pay for prescription drug coverage?
 How to control costs?
These questions remain relevant today and form the
framework for this paper. In addition, the paper contains
a section on options for structuring a Medicare outpatient
prescription drug benefit as well as a glossary.
WHOSE RESPONSIBILITY IS IT TO
PROVIDE COVERAGE?
Many believe that it is the government’s responsi-
bility—through Medicare and Medicaid—to provide an
outpatient prescription drug benefit. Others, however,
argue that the private market should be the vehicle for
expanding drug benefits—through supplemental plans
such as Medigap, through retiree health plans, and
through Medicare risk plans, as they do now to a
limited degree.
The Federal Government:
Medicare Prescription Drug Coverage
In 1969, a task force headed by Philip Lee, M.D.,
was created to study the issue of providing a drug
benefit for beneficiaries of the newly created Medicare
program. While the task force pushed for a Medicare
drug benefit, concerns about associated costs, industry
opposition, and congressional inaction resulted in the
death of that proposal. The 1972 Social Security Act
amendments sparked renewed interest in the notion of
a Medicare prescription drug benefit. Again, the idea
fizzled. While the concept has come and gone through-
out the intervening years—during the 1970s talk of a
national health insurance benefit package; during the
1980s passage and subsequent repeal of the Medicare
Catastrophic Coverage Act; during the 1990s defeat of
President Clinton’s health reform movement; and most
recently during the deliberations of the National Bipar-
tisan Commission on the Future of Medicare—the
Medicare drug benefit has remained elusive. According
to the Wall Street Journal, when asked whether this
Medicare commission will change the course of a
Medicare drug benefit, Lee predicted it would not. “It
is destined to fail,” he replied.1 Time will tell.
The Role of the States
Medicaid coverage of outpatient prescription drugs.
Medicaid provides medical assistance to certain catego-
ries of low-income people, including the aged and
disabled. Under this state-federal program, each state
designs and administers its own program, subject to
federal guidelines. Although they are not required to do
so, all states currently offer outpatient prescription drug
coverage through their Medicaid plans. As a result,
Medicaid provides outpatient prescription drug cover-
age to Medicare beneficiaries who also qualify for some
category of Medicaid benefits. These beneficiaries are
referred to as “dual eligibles.”
Under the Omnibus Budget Reconciliation Act of
1990 (OBRA 1990), Congress enacted several provi-
sions designed to reduce drug expenditures under
Medicaid, including institution of the Medicaid Drug
Rebate Program and mandatory drug utilization review
(DUR) systems. These initiatives are described more
fully in the section entitled “How to Control Costs?”
QMB and SLMB coverage of outpatient prescrip-
tion drugs. Certain low-income Medicare beneficiaries
(qualified Medicare beneficiaries, or QMBs), receive
assistance from Medicaid for payment of Medicare
cost-sharing charges, such as premiums, deductibles,
and coinsurance. These beneficiaries include the elderly
with incomes below the federal poverty line who are not
Medicaid beneficiaries. In some states, however, QMBs
could be full Medicaid beneficiaries; it depends on
where the state sets its income limits.
For Medicare beneficiaries with incomes between
100 percent and 120 percent of poverty (specified low-
income Medicare beneficiaries, or SLMBs), Medicaid
pays only the Part B Medicare premium. Therefore,
although Medicaid will pay the coinsurance charges for
the limited outpatient drugs covered by Medicare (for
QMBs), as well as Part B premiums for both QMBs and
SLMBs, most QMBs and SLMBs do not have access to
Medicaid’s outpatient drug benefit.
State pharmaceutical assistance programs. Since
1975, a number of states have developed drug coverage
programs for low-income elderly or disabled persons
not covered by Medicaid. Currently, 13 states have such
programs (Table 1). These programs are each funded
and operated differently. For example, while several
states use state general funding (Connecticut and
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Table 1
State Pharmaceutical Assistance Programs
Program Name Recipients Enacted
Connecticut ConnPACE 33,798 1986
Delaware Nemours Health Clinic Pharmaceutical Assistance Program 9,335 1981
Illinois Pharmaceutical Assistance Program (PAP) 53,555 1985
Maine Low-Cost Drugs for the Elderly Program 22,000 1975
Maryland Maryland Pharmacy Assistance Program 27,786 1979
Massachusetts Senior Pharmacy Program 65,000
(estimated)
1997
Michigan Michigan Emergency Pharmaceutical Program 10,000 1988
Minnesota Senior Drug Program 4,500 in 1999,
11,600 in 2000
(estimated)
January 1999
New Jersey Pharmaceutical Assistance for the Aged and Disabled
(PAAD)
214,018 1975
New York Elderly Pharmaceutical Insurance Coverage (EPIC) 107,767 1987
Pennsylvania PACE 305,102 1984
Pennsylvania PACENET 1,522 1984
Rhode Island Rhode Island Pharmaceutical Assistance for the Elderly
(RIPAE)
16,000 1985
Vermont Vermont Health Access Program (VHAP) 6,283 1996
Vermont VSCRIP 4,306 1989
Source: National Pharmaceutical Council, Inc., “Pharmaceutical Benefits under State Medical Assistance Programs,” December, 1998, 5-3.
Maryland), others rely on foundations (Delaware), on
cigarette tax revenues (Massachusetts), casino revenue
funds (New Jersey), and state lottery monies (Pennsyl-
vania). Most of these programs also receive some type
of manufacturer rebate.
The Private Marketplace
Given the lack of an outpatient prescription drug
benefit under Medicare, it is not surprising that the
majority of the elderly with drug coverage obtain their
coverage in the private market. Seniors obtain supplemen-
tal coverage for prescription drugs through Medigap
policies, retiree health plans, or Medicare risk plans.
The Medigap market. Beneficiaries have purchased
supplemental insurance (referred to as Medigap poli-
cies) since the inception of the Medicare program as a
way to protect themselves against costs not covered by
the program (for example, outpatient drugs, routine
physicals, and podiatric care). Medigap insurance is
specifically designed to supplement Medicare’s benefits
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and is regulated by federal and state law. Until the
passage of OBRA 1990, however, the Medigap market
lacked standardization among the benefits sold, creating
confusion among consumers. The Medigap provisions
in OBRA 1990, which became effective on July 30,
1992, required all new Medigap policies to conform to
one of ten standardized sets of benefits, or plans. These
range from Plan A, the basic benefit package, to Plan J,
which provides the greatest coverage.
Among other things, OBRA 1990 enabled beneficia-
ries to make informed choices about the benefits they
were purchasing. One of those benefits was outpatient
prescription drug benefits. Plans H, I, and J offer
prescription drug benefits. Plans H and I are structured
with a $250 deductible. After the deductible is met, the
policy covers 50 percent of prescription drug costs to a
maximum benefit of $1,250. Plan J also has a $250
deductible but covers 50 percent of prescription drug
costs to a maximum benefit of $3,000. The costs of
these plans are high in comparison to the other plans (in
part, to compensate for adverse risk selection), and the
coverage is quite limited.
Access to individually purchased Medigap policies
can, in some cases, be limited. Elderly Medicare benefi-
ciaries are guaranteed a six-month open-enrollment
period when they first enroll in Part B at age 65 or older.
Under federal law, at any time after the open-enroll-
ment period, insurers can refuse to issue Medigap
policies on the basis of age or health status and can
impose preexisting condition exclusion periods or
refuse to cover certain conditions at all. Even insurers
that have “guaranteed issue” for Medigap policies
without drug coverage underwrite drug coverage
purchased outside of the open-enrollment period.2
Retiree health plans. Many employers provide health
insurance benefits to their Medicare-eligible retirees as
part of their company retirement package. This insurance
is typically more generous and less costly for the benefi-
ciary than Medigap. Most employer-provided retiree
benefits include outpatient prescription drug coverage.
While the vast majority of retiree health plans offer
outpatient prescription drug coverage, benefit analysts
report that, as a result of changing accounting require-
ments and rising health care costs, the number of employ-
ers offering retiree health coverage is diminishing. In
particular, employers have expressed concern over the
rising cost of providing prescription drug coverage.
Consequently, employers are reconsidering the
package they are willing to offer employees. According
to the recent Mercer/Foster Higgins National Survey of
Employer-Sponsored Health Plans 1998:
Some employers keep the cost of their retiree medical
plans down by excluding prescription drug coverage. In
1998, 24 percent of retiree plan sponsors did not pro-
vide prescription drug coverage to pre-Medicare retir-
ees; 28 percent did not provide it to Medicare-eligible
retirees. This exclusion is rare among the largest em-
ployers; fewer than 10 percent of employers with 10,000
or more employees refuse to cover prescription drugs
for their retirees. Among those sponsors providing drug
coverage to pre-Medicare retirees, half provide a card
plan or mail-order plan (51 and 50 percent, respec-
tively). Among sponsors who provide drug coverage to
Medicare-eligible retirees, 56 percent offer a mail-order
plan and 50 percent offer a card plan.
In response to increasing cost pressures, many
employers are moving their Medicare-eligible retirees
into Medicare managed-care plans, thus reducing
premium and claim costs and allowing companies to
more accurately predict retiree health costs.
Medicare risk plans. Prescription drug coverage is a key
benefit that greatly influences a Medicare beneficiary’s
decision to join an HMO. Although not obligated to do
so, many of the Medicare health maintenance organiza-
tions (HMOs) were quick to offer outpatient prescription
drug coverage in an attempt to gain market share. While
this strategy may have yielded the desired results initially,
much has happened in the marketplace that will change
how Medicare HMOs do business in the future. Analysts
warn that the likelihood of HMOs offering unrestricted
drug coverage in the future is questionable.
Especially problematic for Medicare risk plans, they
maintain, is their attractiveness for patients with a high
number of prescriptions. Further disadvantaging these
plans are the current Medicare rules which allow
beneficiaries to leave a plan with only 30 days notice.
Many beneficiaries exhaust their drug benefits and then
switch to another Medicare risk plan, thus taking
advantage of the new plan’s drug coverage. Beneficia-
ries will be able to move from plan to plan until 2002,
when the rules stipulate a longer commitment. In 2003,
the lock-in period is one year, with an initial three-
month window for beneficiaries to switch plans.
By the end of 1998, some Medicare HMOs withdrew
from the market in part because, according to plan
executives, medical costs were higher than expected
(particularly in the area of prescription drugs), Medicare
payments were lower than expected, and plans were
unable to raise premiums or cut prescription drug cover-
age for the elderly once initial benefit packages were filed
with the Health Care Financing Administration (HCFA).
The pull-out was estimated to affect over 400,000 benefi-
ciaries. These beneficiaries had the option of going back
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into the traditional fee-for-service Medicare program,
with or without supplemental insurance to cover extra
items (such as outpatient prescription drugs), or of
enrolling in another HMO, if available in their market.
Beneficiaries choosing among Medicare HMOs and
other plan options may find the plans difficult to compare.
As explained in the Forum’s Issue Brief No. 723, Com-
municating to Beneficiaries about Medicare+Choice:
Opportunities and Pitfalls, written by Nora Super Jones,
The value of plans’ prescription drug coverage may be
the most difficult to compare. GAO [the General
Accounting Office] found that plans differ in how they
calculate the dollar amounts of drugs used by beneficia-
ries. For example, some plans use retail prices, while
others use average wholesale prices (AWP) or a lower
price discounted from AWP to calculate a member’s
total drug usage in dollars. Therefore, a beneficiary
comparing one plan with an annual cap on prescription
drug coverage of $1,200 with another offering coverage
up to $1,000 may incorrectly assume the first plan is
more generous. In fact, the consumer value of the drug
benefit could vary substantially, depending on how the
HMOs compute the drug cost.
WHO SHOULD BE COVERED?
Despite the absence of a specific Medicare drug
benefit, supplemental coverage does exist for the
majority of the nearly 40 million Medicare-eligible
beneficiaries. Among those covered, there exists a great
deal of variation among the types and level of coverage.
When considering the addition of a Medicare outpatient
drug benefit, policy analysts and legislators will need to
distinguish between anecdotal and statistical reality:
 Who is already covered?
 Is that coverage adequate?
 Is that coverage affordable?
 Will that coverage be there in the long-term?
 Who is not covered?
 Will a Medicare drug benefit duplicate or substitute
for existing coverage?
 Should a Medicare benefit be designed to cover only
those without coverage?
Who Is Covered?
The most recent estimates appeared in the January/
February 1999 issue of Health Affairs, in a Datawatch
piece entitled “Prescription Drug Coverage, Utilization,
and Spending among Medicare Beneficiaries,” by Mar-
garet Davis, et al. Using data from the 1995 Medicare
Current Beneficiary Survey (MCBS), the authors describe
the sources and extent of drug coverage among non-
institutionalized Medicare beneficiaries.
The data show that 65 percent of Medicare beneficia-
ries have some level of drug coverage—a figure much
higher than previous published numbers—and that 95
percent of Medicare health maintenance organization
enrollees have drug coverage.
Table 2 summarizes the distribution of prescription
drug coverage among Medicare beneficiaries based on
the 1995 MCBS data.
Analysts urge caution when citing this 65 percent
number, primarily because of the unevenness of the
coverage. Some of the Medicare beneficiaries counted
in the 65 percent have robust drug coverage through
generous employee retiree plans and Medicare HMOs,
while others—also included in this 65 percent—have
meager coverage and high deductibles through Medigap
policies. Further, beneficiaries were considered to have
drug coverage in this study if they had it at any point
during their eligible months.
Who Is Not Covered?
Most of the Medicare eligible beneficiaries without
supplemental coverage are those with incomes too high
to qualify for Medicaid or other state assistance pro-
grams, those with incomes too low to afford the pur-
chase of supplemental coverage, or those who did not
work for an employer who sponsors retiree coverage.
Many of these elderly cannot afford the out-of-pocket
expenses needed to pay for drugs. According to data from
the American Association of Retired Persons (AARP):
Fee-for-service beneficiaries with annual incomes
below $10,000—who are less likely to have prescrip-
tion drug coverage—were estimated to have spent an
average of 8 percent of their income out-of-pocket for
prescription drugs. By contrast, beneficiaries with
annual incomes above $25,000 were estimated to have
spent an average of 2 percent of income on prescrip-
tion drugs.
Average out-of-pocket payments for drug expenses for
beneficiaries without any form of drug coverage were
$432 in 1995, compared with $232 for those with drug
coverage, according to the HCFA data.
Beneficiaries without prescription drug coverage are
disadvantaged further. Unlike individuals in employer-
sponsored and managed care plans who enjoy volume
discounts, most individuals without drug coverage must
pay
 
retail price for their prescription drugs. These
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individuals can, however, take advantage of competi-
tion at the retail level by shopping around to get a better
price. Also, even without drug coverage, a person can
access a mail-service pharmacy (for example, through
AARP) which generally offers competitive prices,
particularly for chronic condition medications.
WHAT SHOULD BE COVERED?
Under traditional fee-for-service Medicare, coverage
of outpatient prescription drugs is limited. As legislators
consider broadening this benefit, they will have to
consider how generous a benefit to design.
Current Medicare Outpatient Prescription
Drug Coverage
Currently, payment will be made only when a drug
or biologic cannot be self-administered. In other words,
Medicare coverage is generally limited to drugs or
biologics administered by injection. If the injection is
self-administered, as in the case of insulin, for example,
it is not covered under Medicare.
Table 2
Outpatient Drug Coverage among Noninstitutionalized Medicare Beneficiaries, 1995
(by type of supplemental insurance )
Percent of Beneficiaries
with Specified Type of
Supplemental
Insurance
Percent of Beneficiaries
with Each Type of
Supplemental Insurance
Who Have Drug Coverage
Percent of All
Beneficiaries
with Drug
Coverage
Employer Sponsoreda 33% 86% 28%
Medicaidb 12% 90% 11%
Medicare Risk HMO 7% 95% 7%
Individually Purchased (Medigap) 29% 29% 8%
All Otherc 3% 89% 3%
Switched Coverage during the Yeard 8% 80% 6%
No Supplemental Insurance 8% 0% 0%
Total 100% N/A 65%e        
Key: N/A–Not Applicable
Notes: Data are based on noninstitutionalized, community-based population and include those who were enrolled in Medicare at some
point during the year. Each person has been assigned to one supplementary insurance category, but may or may not obtain his or her
drug insurance coverage from that source.
aIncludes those who had only employer-sponsored supplemental insurance and those who had both employer-sponsored and individually
purchased supplemental insurance.
bIncludes beneficiaries receiving full Medicaid benefits, as well as qualified Medicare beneficiaries (QMBs) and specified low-income
Medicare beneficiaries (SLMBs).
cIncludes other public programs such as Veterans Affairs, Department of Defense, and State Pharmaceutical Assistance Programs for
low-income elderly, as well as nonrisk HMOs (cost and health care prepayment plans).
dIncludes beneficiaries who did not spend 100 percent of their Medicare-eligible months in one insurance category.
eColumn does not add up to total due to rounding error.
Source: Michael E. Gluck, Ph.D., “A Medicare Prescription Drug Benefit,” National Academy of Social Insurance White Paper
(forthcoming). Data from M. Davis et al., “Prescription Drug Coverage, Utilization, and Spending among Medicare Beneficiaries,”
Health Affairs 18, no. 1 (January/February 1999): 231-243, and from the Medicare Current Beneficiary Survey.
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Despite these limitations, Medicare law specifically
authorizes coverage for a number of drugs, such as
immunosuppressive drugs following a covered organ
transplant (for 36 months), some vaccines, erythro-
poietin, and oral cancer drugs used in cancer chemo-
therapy when identical to drugs that would be  covered
if not self-administered.
As of January 1, 1998, the Medicare payment amount
for covered drugs is the lesser of (a) the actual charge or
(b) 95 percent of the average wholesale price. For most of
these drugs, Medicare pays 80 percent of its recognized
payment amount once the beneficiary meets the deduct-
ible for Medicare Part B services. With few exceptions,
the beneficiary is responsible for the remaining 20
percent. The president’s fiscal year 2000 budget proposes
to change the payment amount to 83 percent of average
wholesale price.
Because of the way Medicare has historically paid
HMOs, prescription drug coverage under these plans
varies significantly by geographic region. Areas with
high payment rates generally have generous prescrip-
tion drug coverage, while Medicare HMOs in low
payment areas offer no additional benefits beyond what
Medicare traditionally covers. Benefit packages can
also vary markedly within a given region. For example,
on the San Diego area (zip code 92014), Aetna U.S.
Healthcare provides Medicare beneficiaries with an
unlimited generic drug benefit, but brand-name pre-
scription drugs are covered only up to $2,000 per year;
UCSD Health Plan covers generic and brand-name
drugs up to $2,500 per year; and Kaiser Foundation
Health Plan and PacifiCare provide an unlimited
prescription drug benefit. In addition, each of the plans
has a different copayment schedule.3
Future Medicare Outpatient Prescription
Drug Coverage
Not all drugs are created equal. In fact, the very
definition of a “drug” may change.
We live in an era where the line is blurring between
ethical drug products and biotechnology, as well as
drug-device combination products. Determining (a)
What is a drug? (b) Should it be covered? Under what
conditions(s)? (c) How should it be reimbursed? are
all important questions.”4
Presently, analysts are faced with the same set of
questions for today’s breakthrough drugs, which
represent a significant advance over existing therapies,
as well as for “me-too” drugs, which represent slight
variations of existing products.
In addition to determining coverage of breakthrough
and me-too drugs, further consideration will have to be
given to expanding coverage not only to life-extending
products but also to those pharmaceuticals, “recro-
ceuticals,” “cosmeceuticals,” and “nutraceuticals” that
may not extend life but certainly enhance it. For example,
should Medicare pay for every product approved by the
FDA? Should off-label use be covered? Are nutrition
supplements and vitamins to be part of this benefit? Who
should decide what gets covered?
WHO SHOULD PAY FOR
PRESCRIPTION DRUG COVERAGE?
Steve Long’s caution in his 1994 Health Affairs
article still holds: 
Many a meeting on health policy is yet brought to a
pause by the call to “remember the lesson of the
Medicare Catastrophic Coverage Act.” One lesson
clearly pertains to the difficulty of financing coverage
expansions that will benefit only some people, while
using taxes that would be paid by all Medicare en-
rollees. Many people who now have coverage for
prescription drugs are reluctant to depart from
premium-financed approaches that would closely
match incremental contributions to incremental
benefits. On the other hand, many of those without
coverage do not have the means to pay for its full cost.
This argues for broad-based taxes levied on those who
are able to pay, regardless of their current benefits.
The Mechanics of Part B Financing
Should an outpatient prescription drug benefit be
added to Medicare’s core benefit package, it would fall
under what is referred to as Part B. Medicare, a federal
health insurance program, is divided into three parts: Part
A, which, with few exceptions, covers inpatient care; Part
B, which covers outpatient services, such as physician
office visits and medical equipment; and Part C, the
Medicare+Choice program, the most recent addition.
Currently, Medicare Part B, also known as Supple-
mentary Medical Insurance, or SMI (which is different
from Medigap supplemental insurance), is financed by a
combination of beneficiary premiums and general federal
revenues collected from workers, retirees, corporations,
and other federal taxpayers. For 1999, the Part B premium
is $45.50 per month and the annual deductible is $100.
Although Part B is voluntary, virtually all Medicare-
eligible beneficiaries have Part B coverage.
Beneficiary premiums cover about 25 percent of
program costs, while general federal revenues finance
the remaining 75 percent through the Part B Trust
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Fund. In addition to having paid income taxes during
their younger years, it is estimated that people age 65
and older will pay about 9 percent of federal personal
income taxes in 1997. Personal income taxes represent
about 70 percent of general revenues.5
HOW TO CONTROL COSTS?
The issues of pharmaceutical cost and price are
complicated and have become highly politicized over
the past decade. On the one hand, while headlines
—such as the one in a January 25, 1999, New York
Times article—cry out that “Patients Are Facing Sharp
Rise in Costs for Drug Purchases,” other articles,
reports, and analysts caution that short-term cost hikes
should be weighed against the fact that pharmaceuticals
in many cases provide long-term value and, often, cost-
effective care.
Nevertheless, retail prescription drug sales grew
14.1 percent in 1997—faster than other types of health
care spending and the greatest growth since 1990, when
it reached 14.6 percent—according to HCFA data
released in November 1998. HCFA data further re-
vealed that retail prescription drug expenditures rose
from about $5.5 billion in 1970 to some $12 billion in
1980, $37.7 billion in 1990, and $78.9 billion in 1997.6
By all accounts, double-digit pharmaceutical budget
increases are forecast annually for the next three to five
years. Three factors have contributed to the recent
increases in pharmaceutical budgets: unit cost inflation;
utilization (that is, increases in the absolute number of
prescriptions); and intensity (that is, new drug technolo-
gies becoming available). Fueling the increase in
utilization is the explosion of direct-to-consumer
advertising by the pharmaceutical companies, with
some estimates reaching as high as $917 million for
1998.7 The technological explosion that enabled the
extraordinary growth of electronic prescription claims
processing has also contributed to the increase.
In a December 21, 1998, special report on pharma-
ceuticals, BNA reporters pointed out that “an emerging
new mix of drivers—demographic, scientific, eco-
nomic, and regulatory—is helping to engineer the
recent increasing double-digit growth rates in retail
prescription drug sales.”8
Cost Drivers
Demographic. The Council on the Economic Impact of
Health System Change held a conference on “Health
Status, Technological Innovation, and Health Care
Expenditures” on February 9 and 10, 1999, in Washing-
ton, D.C. In the background paper of the same title,
prepared by Cindy Parks Thomas, David Shactman, and
Stuart H. Altman, Ph.D., the authors pointed out the
following:
Indicators typically used to gauge the health of the
population—longevity, mortality, disability, and
disease incidence and prevalence—reveal several
demographic and health trends relevant to health care
utilization and expenditures. They include:
 A growing elderly population, increasing both in
absolute terms and as a proportion of the overall
population;
 Decreasing mortality rates for several high-preva-
lence, high cost diseases such as cardiovascular
disease and stroke;
 Changing patterns of chronic disease prevalence;
 Decreasing disability rates among several segments
of the older population; and
 Improving health-risk behaviors among the elderly
(decreased smoking; better education).
The magnitude and sustainability of each of the above
trends will have direct bearing on health expenditures
over the next decades.
The economic burden resulting from a growing
elderly population will depend upon the extent of
disease and disability among this age group (Table 3).
This will be particularly relevant to the Medicare
program should an outpatient prescription drug benefit
be added.
Scientific. Over the years, Americans have benefitted
from the advances in pharmaceutical research. Leading
causes of death have been eliminated, treatments for
many diseases are taken for granted, vaccines prevent-
ing diseases are commonplace, and life expectancy has
increased. Scientists have come a long way since the
development of penicillin. Today’s pharmaceutical
research has entered the biotechnology era. The Phar-
maceutical Research and Manufacturers of America
(PhRMA) has indicated that, today, over 350 biotech-
nology medicines produced by 140 pharmaceutical and
biotechnology companies, for a variety of diseases, are
in development (that is, in human clinical trials or at the
FDA for approval).
Indeed, the face of pharmaceutical research is
changing (Figure 1). Steve Arlington and Simon
Hughes, authors of a recent PriceWaterhouseCoopers
article, “The Pharmaceutical Industry 2005—A Win-
dow onto the Future,” explain that
discovery throughput has been revolutionized through
extensive investment in new technologies—genomics,
combinatorial chemistry, high throughput screening. 
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Source: Lehman Brothers Pharmaceutical Research
Table 3
Selected Major Chronic Conditions by Age Group, 1995
(per 1,000 persons in each age group)
Prevalence in Age
Group under 45
Prevalence in Age
Group 45-64
Prevalence in Age
Group over 65
Arthritis 29.2 232.9 489.5
Hypertension 32.2 222.7 403.4
Cardiac disease 29.0 120.8 307.7
Diabetes 7.9 63.8 126.4
Cerebrovascular disease
(Stroke) 1.7 14.9 71.3
Source: National Center for Health Statistics, 1998.
Meanwhile, productivity and speed continue to be
transformed through increasing use of CROs (contract
research organizations), massive investment in IT
(information technology) and the setting up of virtual
development organizations or “skunk works.”
Economic. Despite the promising advances in drug
innovation, it is a long and risky undertaking for
pharmaceutical research and manufacturing companies.
It has been estimated that drug companies will invest
$24 billion in drug discovery this year. According to
PhRMA, only three out of ten approved drug products
recover their research and development (R&D) costs.
“Companies must rely on these highly successful products
to fund R&D.” Industry critics point out, however, that
“drug company profits are enormous. The annual profits
of the 10 leading drug companies were nearly $20 billion
last year, according to Fortune magazine.”9
According to manufacturers, patent protection is
critical for the continuation of pharmaceutical innova-
tion. Patents provide research-based pharmaceutical
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companies with a period of market exclusivity, during
which time they have the opportunity to recoup their
R&D investments. During the mid-1980s, passage of
the Drug Price Competition and Patent Term Restora-
tion Act—also referred to as the Hatch-Waxman Act—
made it easier for generic drugs to enter the market.
Sales of generic drugs result in a reduction of returns
that pharmaceutical companies earn from developing
brand-name drugs. Generic drugs cost less than brand-
name drugs, largely because the manufacturers do not
carry the financial burden of R&D costs.
As a July 1998 Congressional Budget Office study
explained:
The Hatch-Waxman Act aimed to limit that effect by
extending the length of time that a new drug is under
patent—and thus protected from generic competitors.
Those extensions compensate for the fact that part of
the time a drug is under patent it is being reviewed by
the FDA rather than being sold. The act tried to
balance two competing objectives: encouraging
competition from generic drugs while maintaining the
incentive to invest in developing innovative drugs.10
According to PhRMA, “In the United States, despite 20
year patent terms, the average period of useful (post-
FDA approval) patent life for new drugs introduced in
the 1990s has been only 11-12 years.”
Regulatory. One of the results of the passage of the
FDA Modernization Act of 1997 was the extension of
the 1992 Prescription Drug User Fee Act, otherwise
known as PDUFA. Among other things, one of the
primary objectives of PDUFA is to streamline the
amount of time required for drug development and
approval. Between 1985 and 1990, for example, the
average number of new product approvals per year was
23. That number jumped to 50 between 1995 and 1998.
It is estimated that by 2002 new products will account
for 41 percent of total sales.
Cost Control Tools
While the clinical benefits of many of these new
products are significant, their high costs place a heavy
burden on payers and patients. As new products make
their way into the market, the market has responded
with new tools to control drug costs. One of the most
dramatic responses has been the growth of pharmacy
benefit managers, or PBMs.
PBMs. The past decade has witnessed the proliferation of
pharmacy benefit managers. PhRMA reports that “these
companies evolved from insurance claim-processing and
mail-order prescription companies. PBMs now provide
managed pharmacy benefits for approximately half the
insured population in the United States.” The relation-
ships between PBMs and pharmaceutical companies as
well as between PBMs and pharmacies are shifting.
Recently, there has been a lot of activity in the buying and
selling of PBMs. Some question whether PBMs, espe-
cially those owned by drug companies or by drug store
chains, are necessarily freestanding companies.
Using purchasing techniques such as pharmacy
networks, negotiated discounts and rebates, lists of
preferred drugs, and online utilization review, PBMs
enhance the ability of employers and health plans to
contend with pharmaceutical prices, physician prescribing
practices, and rising drug expenditures. Leading firms are
also pioneering new methods of disease management.11
Many of the cost-saving tools used by PBMs are not
new. Copays and deductibles, for example, are standard
fare among health plans. In response to rising drug
costs, insurers, such as Cigna Corp., began a three-
tiered copay arrangement in 1998: $5 for generics, $15
to $20 for preferred brand-name drugs, and $35 to $40
for nonpreferred brand-name drugs. In 1995, Cigna
members paid only a $5 copay for preferred drugs—
generic or brand-name.
Similarly, most plans and PBMs have instituted
many of the following cost-control tools (all of which
are defined in the glossary at the end):
 formulary;
 generic substitution; 
 drug utilization review;
 step-care therapy;
 therapeutic substitution;
 prior approval;
 mail-order pharmacies; and
 disease management.
Negotiated discounts. Negotiating discounts for
pharmaceuticals is a common practice. PBMs and
managed care plans negotiate discounts in exchange for
the ability to move market share, while the federal
government (for example, the Veterans Health Admin-
istration, the Public Health Service, and the Indian
Health Service) mandates discounts.
Senior citizens without drug coverage generally do
not enjoy the benefits of “preferred pricing.” During the
summer of 1998, minority staff of the House Govern-
ment Reform and Oversight Committee conducted 20
studies around the country to monitor the prices of best-
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selling drug products for the
elderly. Staff analysis found that
elderly individuals paying cash
(as opposed to using a discount
drug card) paid significantly
more money for the same medi-
cation than drug manufacturers’
most favored customers. How-
ever, some analysts have ques-
tioned aspects of the study’s
methodology (that is, base prices
used for comparison). Figure 2
highlights findings from the
study.
A new congressional Prescrip-
tion Drug Task Force was created
in response to the price discrimi-
nation found by minority commit-
tee staff. Rep. Marion Berry (D-
Ark.) and Rep. Tom Allen (D-
Maine) serve as cochairs of the task force. On September
25, 1998, the co-chairs introduced H.R. 4627, the Pre-
scription Drug Fairness Act of 1998, which would allow
pharmacies that serve Medicare beneficiaries to purchase
prescription drugs at the low prices available to federal
agencies under the Federal Supply Schedule. Nothing in
the bill requires the pharmacy to pass its savings on to the
Medicare beneficiaries, however, although a bill summary
estimates that this legislation could reduce prices for
seniors by over 40 percent. Others point out that, as a
result of these savings, prescription drug prices could go
up elsewhere—the classic balloon phenomenon.
Rebates. OBRA 1990 established the Medicaid rebate
program. The basic formula requires that, in exchange for
having their product(s) reimbursed (that is, on the formu-
lary), pharmaceutical manufacturers rebate to the states
the greater of (a) 15.1 percent of the average manufac-
turer price (AMP) paid by wholesalers for brand-name
drugs that Medicaid beneficiaries purchase as outpatients
or (b) the manufacturer’s “best price.” The best price is
the lowest price offered to any other customer, excluding
Federal Supply Schedule prices and prices to state phar-
maceutical assistance programs. Similarly, manufacturers
pay a rebate equal to 11 percent of the AMP on generic
and over-the-counter drugs.
If a brand-name drug’s AMP increases faster than the
inflation rate, an additional rebate is imposed so that
manufacturers cannot offset the basic rebate by raising
their AMP. The additional rebate is equal to the differ-
ence between the current AMP and a base-year AMP
increased by the inflation rate as measured by the
consumer price index.12
Medicaid—which accounted for over $2.2 billion
worth of pharmaceutical manufacturer rebates in
1997—is not alone in its use of rebates. As the number of
HMOs and PBMs increased, manufacturers began to
offer rebates in an effort to gain access to managed care
patients. According to a May 1997 American Druggist
article, “Tug-of-War over Rebates,” by Robert DiChiara,
Patricia Pesanello, and Ellen Cappelino, rebates flow
from the manufacturer through the PBM and are split with
the benefit plan of the HMO or employer (Figure 3).
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When considering the use of PBMs, rebates, and
best price for a Medicare benefit, it is important for
policy and legislative analysts to note that each pharma-
ceutical company is structured differently and prices its
products differently. Thus, the effects of such policies
vary widely from company to company.
OPTIONS FOR STRUCTURING A
MEDICARE OUTPATIENT
PRESCRIPTION DRUG BENEFIT
The following components are all considerations in
the design of a Medicare outpatient prescription drug
benefit. These categories are merely representative of
the elements involved in designing such a benefit, and
are not meant to be exhaustive. Depending upon how
the debate unfolds and how a benefit might be de-
signed, issues of adverse risk selection, income distribu-
tion, locus of control, interface with existing drug
benefits, as well as long-term implications of future
pharmaceutical research and development investment
will be paramount. Each option is associated with trade-
offs—political, financial, competitive, and practical:
Type of Benefit
 Standard, broad-scale benefit for all beneficiaries
(with or without cap)
 Catastrophic coverage only
 Targeted benefit for those without any other cover-
age (For example, the federal government could
require prescription drug coverage for QMBs and
SLMBs or encourage state pharmaceutical assis-
tance programs by offering matching grants)
 Voluntary, supplemental coverage
Benefit Structure
 Amended Medicare Part B (traditional fee-for-
service Medicare beneficiaries)
 Mandated drug benefit for all standard Medigap plans
 Federal government financial contribution to help
Medicare beneficiaries purchase a health plan
(Beneficiaries would be free to select from a range
of private-sector options the plan that best meets
individual needs. [This option represents the
PhRMA proposal])
Eligibility Criteria
 Age
 Disability
 Income level/wealth (single, married)
 Preexisting conditions
Type of Insurance
 Community rating
 Experience rating
 Age rating
Market Structure
 Universal or voluntary coverage
 Plan choices
 Basis of competition
 Risk adjusters
 Market rules
 Benefit design
 Flexibility or standardization
Financing
 Beneficiary premiums
 Federal general revenues
 Payroll or other targeted tax
 Government surpluses
 Savings from competition (or other reforms)
Beneficiary Cost-sharing
 Additional drug deductible 
 Increased deductible
 Co-pays or coinsurance (differential, based upon
generic, preferred, or brand name product)
 Out-of-pocket limits (individual/couple)
Reimbursement
 Pharmacy Payment
– Dispensing fee
– Ingredient reimbursement basis
– Cognitive services
 Drug Price
– Manufacturer rebates
– Best price
– Price negotiated by HCFA directly with manu-
facturer
Benefit Administration
 Pharmacy Benefit Management (many technical
operational questions to resolve)
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– Capitated or noncapitated basis
 Carve-out program for drugs
 Government-administered benefit
Cost/Utilization Management
 Formulary (open, closed, national)
 Use of generics
 Prior authorization
 Therapeutic substitution
 Disease management
 Mail service
 Price controls
 Prescribing/dispensing limits
– Quantity (that is, limited to 30-day supply or 100-
unit dosage, whichever is greater)
– Dollar limits
Quality Assurance
 Drug utilization review
 Cognitive services
ENDNOTES
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Glossary
Unless otherwise indicated, these terms were taken
from the December 1998 National Pharmaceutical
Council’s (NPC’s) Pharmaceutical Benefits under State
Medical Assistance Programs and a CBO study, “How
Increased Competition from Generic Drugs Has Af-
fected Prices and Returns in the Pharmaceutical Indus-
try,” July 1998.
Actual Acquisition Cost: The pharmacist’s net pay-
ment made to purchase a drug product, after taking into
account items such as purchasing allowances, dis-
counts, and rebates. (NPC)
Average Manufacturer Price (AMP): The average
price paid by wholesalers for products distributed to the
retail class of trade. (NPC)
Average Wholesale Price (AWP): The published
suggested wholesale price of a drug. It is often used by
pharmacies as a cost basis for pricing prescriptions.
(NPC)
Best Price: For purposes of Medicaid rebate calcula-
tions, lowest price paid for a product by any purchaser
other than federal agencies and state pharmaceutical
assistance programs. (NPC)
Brand-Name Drug: See Innovator Drug.
Card Programs: The use of a drug benefit identifica-
tion card which, when presented to a participating
pharmacy by employees or their dependents, usually
entitles them to receive the medication for a copay.
(NPC)
Carve Out: A decision to purchase separately a service
that is typically a part of an indemnity or HMO plan.
Example: an HMO may “carve out” the behavioral
health benefits and select a specialized vendor to supply
these services on a stand-alone basis. (NPC)
Compliance: The degree to which patients follow
treatment recommendations. (NPC)
Concurrent Drug Evaluation: An electronic assess-
ment of claims at the point of service to detect potential
problems that should be addressed prior to dispensing
drugs to patients. (NPC)
Contract Pharmacy System: Pharmaceutical benefit
delivery arrangement in which an HMO contracts with
community pharmacies (chain or selected independents)
to provide medications to members. Reimbursement
may be by fee-for-service, capitation, or some other
arrangement. (NPC)
Counter Detailing: A process of re-educating or
influencing prescribers in a closed or controlled HMO
plan. Usually done in order to gain more compliance
with a formulary. In a counter-detailing program,
techniques used by pharmaceutical sales representatives
are adapted to a “counter” objective, that is, to provide
doctors with basic pharmacological information de-
signed to influence their prescribing habits. (NPC)
Disease Management: An effort to improve patient
outcomes and lower costs by organizing managed care
initiatives around patients with a particular disease or
condition. (NPC)
Day Supply Maximum: The maximum amount of
medication a person may receive at one time, usually
the amount needed for 30 (acute) or 90 (maintenance)
days of therapy, as defined by the drug benefit. (NPC)
Dispense as Written (DAW): A prescribing directive
issued by physicians to indicate that the pharmacy
should not in any way alter a prescription. Such alter-
ations are usually done in order to substitute a generic
drug for the brand-name drug ordered. (NPC)
Dispensing, Fill, or Professional Fee: The amount
paid to a pharmacy for each prescription, in addition to
the negotiated formula for reimbursing ingredient cost.
(NPC)
Drug Detailing: Presenting information about a brand-
name drug product to prescribers to educate them about
its activity, uses, side effects, proper dosage and admin-
istration, etc. (NPC)
Drug Formulary: A listing of prescription medications
which are preferred for use by a health plan and which
may be dispensed through participating pharmacies to
covered persons. This list is subject to periodic review
and modification by the health plan. A plan that has
adopted an “open or voluntary” formulary allows
coverage for both formulary and nonformulary medica-
tions. A plan that has adopted a “closed, select or
mandatory” formulary limits coverage to those drugs in
the formulary. (NPC)
Drug Use Evaluation (DUE): Evaluations of prescrib-
ing patterns of prescribers to specifically determine the
appropriateness of drug therapy. There are three forms
of DUE: prospective (before or at the time of prescrip-
tion dispensing), concurrent (during the course of drug
therapy), and retrospective (after the therapy has been
completed). Same as Drug Utilization Review. (NPC)
Drug Utilization: The prescribing, dispensing, admin-
istering, and ingestion or use of pharmaceutical prod-
ucts. (NPC)
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Drug Utilization Review (DUR): A quantitative
evaluation of prescription drug use, physician prescrib-
ing patterns, or patient drug utilization to determine the
appropriateness of drug therapy. Most often focuses on
overutilization. (NPC)
Estimated Acquisition Cost (EAC): An estimate of
the price generally, and currently, paid by providers for
a drug marketed or sold by a particular manufacturer or
labeler in the package size most frequently purchased
by providers. (NPC)
Fixed Fee: An established “fee” schedule for pharmacy
services allowed by certain government and private
third-party programs in lieu of cost-of-doing-business
markups. (NPC)
Formulary: See Drug Formulary.
Generic Drug: a copy of an innovator drug, containing
the same active ingredients, that the FDA judges to be
comparable in terms of such factors as strength, quality,
and therapeutic effectiveness. Generic copies may be
sold after the patent on a brand-name drug has expired.
Generic drugs are generally sold under their chemical
name rather than under a brand name. (CBO)
Generic Substitution: Dispensing a generic drug in
place of a brand-name medication. (NPC)
Innovator Drug: A drug that receives a patent on its
chemical formulation or manufacturing process, obtains
approval from the FDA after extensive testing, and is
sold under a brand name. Also known as Brand-Name
Drug. (CBO)
Legend Drug: A drug that, by law, can be obtained
only by prescription and bears the label, “Caution:
federal law prohibits dispensing without a prescription.”
See Prescription Medicine. (NPC)
Maximum Allowable Cost (MAC), or “Reasonable
Cost Range”: A maximum cost is fixed for which the
pharmacist can be reimbursed for selected products, as
identified in a formulary. (NPC)
Me-Too Drug: A brand-name drug that uses the same
therapeutic mechanism as a breakthrough drug and
therefore competes with it directly. (CBO)
Most Favored Nations Discount or Clause: A con-
tractual arrangement that stipulates that a vendor must
provide to a particular payor the lowest prices that
would be available to any purchaser. The federal
government often invokes most favored nation clauses
for healthcare contracts. (NPC)
Multiple-Source Drug: A drug available in both
brand-name and generic versions from a variety of
manufacturers. (CBO)
National Drug Code (NDC): A national classification
system for identification of drugs. Similar to the Uni-
versal Product Code (UPC). (NPC)
Over-the-Counter (OTC): A drug product that does
not require a prescription under federal or state law.
(NPC)
Pharmacy and Therapeutics (P&T) Committee: An
organized panel of physicians and pharmacists from
varying practice specialties, who function as an advisory
panel to the plan regarding the safe and effective use of
prescription medications. Often comprises the official
organizational line of communication between the
medical and pharmacy components of the health plan. A
major function of such a committee is to develop, manage
and administer a drug formulary. (NPC)
Prescribed Drugs: Prescribed drugs are drugs dis-
pensed by a licensed pharmacist on the prescription of
a practitioner licensed by law to administer such drugs,
and drugs dispensed by a licensed practitioner to his
own patients. This item does not include a practitioner’s
drug charges that are not separable from his other
charges, or drugs covered by a hospital bill. (NPC)
Prescription Medication: A drug which has been
approved by the Food and Drug Administration and
which can, under federal and state law, be dispensed
only pursuant to a prescription order from a duly
licensed prescriber, usually a physician. (NPC)
Prior Approval or Prior Authorization: The process
of obtaining prior approval as to the appropriateness of
a service or medication. Prior authorization does not
guarantee coverage. (NPC)
Rational Drug Therapy: Prescribing the right drug for
the right patient, at the right time, in the right amount,
and with due consideration of relative cost. (NPC)
Rebate: A monetary amount that is returned to a payer
from a prescription drug manufacturer based upon
utilization by a covered person or purchases by a
provider. (NPC)
Restrictive Formulary: A term often used synony-
mously with closed formulary. See Drug Formulary.
(NPC)
Single-Source Drug: A brand-name drug that is still
under patent and thus is usually available from only one
manufacturer. (CBO)
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Step-Care Therapy: Requires that physicians follow
a sequence of treatments for a given condition, usually
starting with the lowest-cost treatment and progressing
to higher-cost treatments only if previous treatments are
not effective. (PhRMA 1998 Industry Profile)
Therapeutic Alternatives: Drug products containing
different chemical entities but which should provide
similar treatment effects, the same pharmacological
action or chemical effect when administered to patients
in therapeutically equivalent doses. (NPC)
Therapeutic Substitution: Dispensing by a pharmacist
of a product different from that which was prescribed,
but which is deemed to be therapeutically equivalent. In
most states, such a practice requires the prescribing
physician’s authorization before the substitution may
occur. A pharmacy and therapeutics committee most
often approves the rationale for therapeutic equivalency
prior to such practice. (NPC)
